Abbisko Cayman (FRA:8ZD) Total Receivables: €1.82 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8ZD Abbisko Cayman Ltd FRA:8ZD
55 GF Score
Price €1.18
GF Value €1.38
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Abbisko Cayman Total Receivables?

Abbisko Cayman FRA:8ZD -0.84% 55 Total Receivables is €1.82 Mil as of Dec. 2025. GuruFocus rates FRA:8ZD with a GF Score™ of 55/100 and a GF Value™ of €1.38 (Fairly Valued). The stock has 6 warning signs investors should review.

Abbisko Cayman's Total Receivables for the quarter that ended in Dec. 2025 was €1.82 Mil.

Abbisko Cayman Total Receivables Related Terms

Abbisko Cayman Total Receivables Historical Data

* Premium members only.

The historical data trend for Abbisko Cayman's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abbisko Cayman Total Receivables Chart

Abbisko Cayman Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial 3.68 5.94 6.13 2.11 1.82

Abbisko Cayman Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.13 6.44 2.11 6.51 1.82
FRA:8ZD
55GF Score
Abbisko Cayman Ltd FRA:8ZD
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abbisko Cayman Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €1.82 Mil mean?
Abbisko Cayman (FRA:8ZD) has a Total Receivables of €1.82 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Abbisko Cayman and its competitors.
Is Abbisko Cayman's Total Receivables too high?
Abbisko Cayman's current Total Receivables is €1.82 Mil. Overall, Abbisko Cayman has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Abbisko Cayman's Total Receivables compare to VRTX and REGN?
Abbisko Cayman's Total Receivables of €1.82 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Abbisko Cayman and its competitors. Abbisko Cayman's current Total Receivables is €1.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbisko Cayman stock overvalued right now?
Based on GuruFocus' analysis, Abbisko Cayman (FRA:8ZD) is currently considered Fairly Valued. The stock's GF Value™ is €1.38, compared to a current price of €1.18 — trading 14.5% below its estimated fair value. The current Total Receivables is €1.82 Mil. Abbisko Cayman's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Abbisko Cayman (FRA:8ZD), the current Total Receivables is €1.82 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abbisko Cayman (FRA:8ZD) Overvalued in 2026?

Based on GuruFocus' analysis, Abbisko Cayman stock appears to be undervalued. The current stock price of €1.18 is trading 14.5% below its estimated GF Value™ of €1.38. GuruFocus considers Abbisko Cayman to be Fairly Valued.

Key valuation signals for FRA:8ZD:

  • Total Receivables: €1.82 Mil
  • GF Value™: €1.38 vs. price of €1.18 (14.5% below fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the FRA:8ZD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abbisko Cayman Business Description

Other Exchanges 02256:Hong Kong
Address Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of medicines and differentiated small molecule oncology therapies. The company has pipeline of 21 program candidates, with a primary focus on oncology and pimicotinib has received approval from the China NMPA, and several other candidates are currently in clinical development stage. The company has only one business segment which is the development of medicines. Geographically, the company has it's concentration in European Union and Chinese mainland region.
55GF Score

Get the complete analysis for FRA:8ZD

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.18
Price
€1.38
GF Value